Andreini, Daniele http://orcid.org/0000-0002-9777-8104
Belmonte, Marta
Penicka, Martin
Van Hoe, Lieven
Mileva, Niya
Paolisso, Pasquale
Nagumo, Sakura
Nørgaard, Bjarne L.
Ko, Brian
Otake, Hiromasa
Koo, Bon-Kwon
Jensen, Jesper Møller
Mizukami, Takuya
Munhoz, Daniel
Updegrove, Adam
Taylor, Charles
Leipsic, Jonathon
Sonck, Jeroen
De Bruyne, Bernard
Collet, Carlos
Article History
Received: 25 April 2023
Revised: 3 July 2023
Accepted: 30 July 2023
First Online: 5 October 2023
Declarations
:
: The scientific guarantor of this publication is Prof. Daniele Andreini.
: Bjarne Linde Norgaard and Jesper Moller Jensen have received unrestricted institutional research grants from HeartFlow Inc. Hiromasa Otake reports are receiving research grants from Abbott Vascular; and speaker fees for HeartFlow and Abbott Vascular. Bon-Kwon Koo reports institutional research grants provided by HeartFlow, Inc. Jonathon Leipsic is a consultant and holds stock options in Circle CVI and HeartFlow. He reports a research grant from GE and modest speaker fees for GE and Philips. Bernard De Bruyne reports receiving consultancy fees from Boston Scientific, and Abbott and receiving research grants from Coroventis Research, Pie Medical Imaging, CathWorks, Boston Scientific, Siemens, HeartFlow Inc., and Abbott Vascular. Carlos Collet reports receiving research grants from Biosensor, Coroventis Research, Medis Medical Imaging, Pie Medical Imaging, CathWorks, Boston Scientific, Siemens, HeartFlow Inc., and Abbott Vascular; and consultancy fees from Heart Flow Inc, Opsens, Abbott Vascular, and Philips Volcano. Daniele Andreini reports research grants from GE Healthcare and Bracco. Marta Belmonte, Pasquale Paolisso, and Daniel Munhoz report research grants provided by the Cardiopath Ph.D. program.The other authors have nothing to disclose.
: No complex statistical methods were necessary for this paper.
: Written informed consent was obtained from all subjects (patients) in this study.
: Institutional Review Board approval was obtained.
: Some study subjects or cohorts have been previously reported in the Precise Percutaneous Coronary Intervention Plan (P3) trial (NCT03782688). This is a sub-analysis of the P3 study.
: • prospective• observational• multicenter study